Today: 11 April 2026
Subscribe
Browse Category

Pharmaceuticals 27 January 2026 - 29 January 2026

Olema Pharmaceuticals (OLMA) stock jumps 6% in a weak market — what to watch next

Olema Pharmaceuticals (OLMA) stock jumps 6% in a weak market — what to watch next

Olema Pharmaceuticals shares rose 5.8% to $25.99 Thursday afternoon, adding about $127 million in market value as broader indexes fell. Trading volume reached 926,000 shares. No new company news emerged, but traders are watching for Olema’s March update and progress on its late-stage palazestrant trial. The company reported over $500 million in cash and equivalents as of Dec. 31, 2025.
29 January 2026
··
Johnson & Johnson stock price drifts after record-area run as Morgan Stanley upgrade keeps spotlight on new drugs

Johnson & Johnson stock price drifts after record-area run as Morgan Stanley upgrade keeps spotlight on new drugs

Johnson & Johnson shares slipped 0.1% to $227.43 by midday Thursday after peaking near record highs, following a Morgan Stanley upgrade and a price target hike to $262. The FDA approved a new Darzalex Faspro combination for multiple myeloma on Jan. 27. CEO Joaquin Duato’s spouse sold 100,000 shares last week, SEC filings show. J&J forecasts 2026 sales up to $100.5 billion and EPS up to $11.63.
29 January 2026
··
Eli Lilly stock price today: LLY rises on $1.93 billion Repertoire deal as earnings near

Eli Lilly stock price today: LLY rises on $1.93 billion Repertoire deal as earnings near

Eli Lilly shares rose 0.5% Thursday after Repertoire Immune Medicines announced a partnership with the company worth up to $1.93 billion. The deal follows Lilly’s $1.12 billion gene-editing agreement targeting hearing loss. Investors are also watching for Medicare’s plan to include Trulicity in upcoming price negotiations. Lilly’s earnings report is expected Feb. 4.
29 January 2026
····
GSK shares tick higher after Citi’s neutral call as Feb. 4 results loom

GSK shares tick higher after Citi’s neutral call as Feb. 4 results loom

GSK shares rose 0.34% to 1,823.75 pence early Thursday in London after a 2.42% drop Wednesday. Citi began coverage with a Neutral rating and a 1,900p target, noting pipeline improvements but warning on valuation. Investors await GSK’s Feb. 4 earnings for updates on vaccines, HIV treatments, and 2026 guidance. GSK’s RSV vaccine Arexvy recently gained EU approval for adults 18 and older.
29 January 2026
··
Johnson & Johnson stock price rises as Morgan Stanley upgrades JNJ and FDA clears new Darzalex regimen

Johnson & Johnson stock price rises as Morgan Stanley upgrades JNJ and FDA clears new Darzalex regimen

Johnson & Johnson shares rose 1.5% to $227.72 Wednesday after Morgan Stanley upgraded the stock and raised its price target to $262. The FDA approved expanded use of J&J’s Darzalex Faspro for newly diagnosed multiple myeloma patients ineligible for stem cell transplants. A regulatory filing showed CEO Joaquin Duato’s spouse sold about $22 million in shares.
29 January 2026
··
Johnson & Johnson stock rises on Darzalex Faspro FDA nod as traders size up drug-pricing risks

Johnson & Johnson stock rises on Darzalex Faspro FDA nod as traders size up drug-pricing risks

Johnson & Johnson shares rose 1.2% to $227.06 after the FDA approved Darzalex Faspro for use with the VRd regimen in newly diagnosed multiple myeloma patients ineligible for stem cell transplant. The approval is based on the CEPHEUS trial, which showed improved outcomes. The move comes as Medicare named 15 drugs for future price negotiations, pressuring the sector.
28 January 2026
··
Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer shares fell 1.8% to $26.02 after U.S. Medicare included Xeljanz in its upcoming drug price negotiations, set to begin in 2026 with prices effective in 2028. The Centers for Medicare & Medicaid Services named 15 drugs for talks, and companies must decide by February 28 whether to participate. Investors are awaiting Pfizer’s February 3 earnings for updates on pricing risks.
28 January 2026
······
Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

Eli Lilly shares fell 2.4% to $1,015.05 Wednesday after the company announced a gene-editing deal with Seamless Therapeutics worth up to $1.12 billion. The U.S. government included Lilly’s Trulicity in the next round of Medicare drug-price negotiations, raising pricing concerns. Obesity drug rivals increased ad spending, intensifying competition.
28 January 2026
···
Pfizer stock dips after Xeljanz lands on Medicare price-talk list, with earnings looming

Pfizer stock dips after Xeljanz lands on Medicare price-talk list, with earnings looming

Pfizer shares fell 1.7% to $26.06 after CMS selected its arthritis drug Xeljanz for Medicare price negotiations, with new prices set for 2028. Xeljanz accounted for about $1.01 billion in Medicare spending in the latest period. Investors await Pfizer’s Feb. 3 quarterly results and a Feb. 28 CMS deadline for drugmakers to sign participation agreements.
28 January 2026
···
GSK share price slips in London as Arexvy EU expansion sinks in; earnings next week in focus

GSK share price slips in London as Arexvy EU expansion sinks in; earnings next week in focus

GSK shares dropped 1.8% to 1,828.5 pence by mid-morning Wednesday in London, reversing gains from earlier in the week. The decline followed news that the European Commission expanded approval of GSK’s RSV vaccine Arexvy to all adults 18 and older. Pfizer also secured similar approval for its RSV shot. Investors await guidance from European health agencies and GSK’s earnings report on February 4.
28 January 2026
···
Why Gilead stock hit a fresh 52-week high as Medicare targets Biktarvy and earnings loom

Why Gilead stock hit a fresh 52-week high as Medicare targets Biktarvy and earnings loom

Gilead Sciences shares rose 2.3% to $140.97 Tuesday, hitting a 52-week high after Medicare named its HIV drug Biktarvy for price negotiations starting in 2028. Trading volume topped 10.5 million shares. CEO Daniel O’Day sold 115,640 shares last week under a pre-set plan. Gilead will report fourth-quarter and full-year results after markets close on Feb. 10.
28 January 2026
···
Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next

Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next

Johnson & Johnson shares rose 1.3% Tuesday after the FDA approved a Darzalex Faspro combination for newly diagnosed multiple myeloma patients ineligible for stem-cell transplants. The S&P 500 closed at a record high, while healthcare stocks broadly fell after a Medicare payment proposal. The U.S. also named 15 drugs for future Medicare price negotiations, increasing pressure on big pharma.
28 January 2026
···
Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly shares closed down 2.3% at $1,039.51 Tuesday, then rose 0.3% after hours. U.S. Medicare officials named Lilly’s Trulicity among 15 drugs for 2028 price negotiations. The stock has dropped three straight sessions and now trades about 8% below its Jan. 8 peak. Investors await Lilly’s Feb. 4 earnings for updates on diabetes and obesity drug trends.
28 January 2026
·······
Eli Lilly stock edges up as Roche obesity-drug data keeps weight-loss race in view

Eli Lilly stock edges up as Roche obesity-drug data keeps weight-loss race in view

Eli Lilly shares rose 0.4% to $1,067.38 Tuesday, outperforming a weaker health-care sector as investors awaited the company’s Feb. 4 results. Roche reported its experimental obesity drug CT-388 achieved up to 22.5% placebo-adjusted weight loss in a Phase II trial and plans two Phase III studies this quarter. Novo Nordisk shares slipped. Investors remain focused on demand and supply for Lilly’s weight-loss drugs.
27 January 2026
·
AbbVie stock price closes higher; what to watch next for ABBV ahead of Fed week and earnings

AbbVie stock price closes higher; what to watch next for ABBV ahead of Fed week and earnings

AbbVie shares closed up 0.7% at $220.77 on Monday, moving with broader Wall Street gains ahead of the Federal Reserve’s policy decision and major tech earnings. The company will report full-year and Q4 results before the market opens on Feb. 4. AbbVie recently signed a $650 million cancer drug licensing deal with RemeGen and faces investor scrutiny over its post-Humira growth strategy.
27 January 2026
···
1 … 7 8 9 10 11 … 38

Stock Market Today

  • Cocoa Prices Rise as Dollar Weakness Triggers Short Covering Amid Supply, Demand Concerns
    April 11, 2026, 3:25 AM EDT. Cocoa prices surged with May ICE NY cocoa up 2.66% and London cocoa gaining 2.37%, driven by short covering after dollar weakness. London fund shorts hit an 8-year high, adding fuel to the rally. Despite increased shipments from Ivory Coast and record ICE inventories signaling ample supply, drought in West Africa and fertilizer cost rises from Strait of Hormuz closure support prices. Demand remains weak; Easter chocolate sales estimate a 5% drop, with Barry Callebaut reporting a 22% sales volume decline. European cocoa grindings fell 8.3% year-on-year in Q4, exceeding expectations, reflecting ongoing consumption challenges amid high chocolate prices.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 11.04.2026

11 April 2026
LIVEMarkets rolling coverageStarted: April 11, 2026, 12:00 AM EDTUpdated: April 11, 2026, 3:35 AM EDT Cocoa Prices Rise as Dollar Weakness Triggers Short Covering Amid Supply, Demand Concerns April 11, 2026, 3:25 AM EDT. Cocoa prices surged with May ICE NY cocoa up 2.66% and London cocoa gaining 2.37%, driven by short covering after dollar weakness. London fund shorts hit an 8-year high, adding fuel to the rally. Despite increased shipments from Ivory Coast and record ICE inventories signaling ample supply, drought in West Africa and fertilizer cost rises from Strait of Hormuz closure support prices. Demand remains weak; Easter
UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 11:59 PM EDT Orora ASX:ORA Faces Earnings Reset After Saverglass Impact and Middle East Disruptions April 10, 2026, 11:59 PM EDT. Orora (ASX:ORA) shares plunged over 8% in one day following a guidance update that revealed an earnings reset at its Saverglass unit due to Middle East supply chain disruptions and a shutdown at the Ras Al Khaimah glass plant. Despite a sharp short-term loss, Orora's 90-day share price rise exceeds 33%, contrasting a longer-term 10.58% annual total shareholder return decline amid ongoing sector pressures. Trading at A$1.49,
Go toTop